glp-1 agonists anxiety side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Mapping the effectiveness and risks
Description
The highly anticipated phase 3 EVOKE trial readout found that semaglutide did not significantly reduce progression of Alzheimer's disease
HbA1c and weight cohorts were analysed separately using an ANCOVA model
John Roxborough, MD, we serve patients in Bethesda, Wheaton, Potomac, Falls Church, Tysons Corner, Gaithersburg, Baltimore and McLean Virgin
Its a peptide
